Madison Small Cap Fund Divests Confluent Stake After Acquisition Announcement
Money

Madison Small Cap Fund Divests Confluent Stake After Acquisition Announcement

authorBy Ramit Sethi
DateMar 16, 2026
Read time2 min

Madison Small Cap Fund made a strategic decision to exit its investment in Confluent, Inc. (CFLT) after IBM announced its intention to acquire the data streaming platform provider for $11 billion. This move, which involved selling shares above $30 each, allows the fund to explore new investment avenues. This action comes after a challenging fourth quarter in 2025 where the fund's performance lagged its benchmark, the Russell 2000 Index, primarily due to underperformance in the healthcare sector. Despite current market speculations, the fund remains cautiously optimistic about future opportunities.

Madison Small Cap Fund Sells Confluent Shares Following IBM Acquisition Deal

In a significant corporate development, Madison Small Cap Fund announced on March 16, 2026, its complete divestment from Confluent, Inc. (NASDAQ: CFLT). This decision was prompted by IBM's public declaration to acquire Confluent for a reported sum of $11 billion, equating to $31 per share. This price represented a substantial premium of approximately 35% over Confluent's closing price on the preceding Friday. The management of Madison Small Cap Fund indicated that they do not foresee any rival bids for Confluent, making the sale at over $30 per share a timely move to capitalize on the acquisition news. The proceeds from this sale are earmarked for fresh investment opportunities that align with the fund's evolving strategy. Confluent, a prominent technology firm specializing in data streaming platforms, has been instrumental in assisting clients to seamlessly integrate their applications, systems, and data layers within cloud environments. As of March 13, 2026, Confluent's stock closed at $30.67 per share, demonstrating a modest one-month return of 0.36% and an impressive 12.76% gain over the past 52 weeks, pushing its market capitalization to $11.019 billion.

This strategic divestment by Madison Small Cap Fund highlights the dynamic nature of investment decisions in response to major corporate events. It underscores the importance for fund managers to constantly evaluate their portfolios and reallocate capital to optimize returns and manage risks. The fund's proactive approach in exiting a position post-acquisition announcement, especially when no higher bids are anticipated, reflects sound financial management. Furthermore, the fund's cautious optimism despite a challenging quarter indicates a forward-looking perspective, emphasizing adaptability and the continuous pursuit of growth opportunities within a volatile market landscape.

More Articles
Cryptocurrency Markets See Significant Gains, Bitcoin Tops $73,000
On Monday morning, Bitcoin surged past the $73,000 mark, propelled by substantial ETF inflows. Ethereum, XRP, and Dogecoin also experienced rallies, leading to a generally neutral market sentiment. Meme coin market capitalization saw a nearly 5% increase.
By Scott PapeMar 16, 2026
Madison Small Cap Divests from Cogent Communications Due to Strategic Concerns
Madison Small Cap Fund has exited its investment in Cogent Communications Holdings (CCOI), citing concerns over the company's dividend suspension and elevated leverage. The fund's initial thesis relied on a dividend cut and EBITDA growth, but a temporary suspension led to uncertainty regarding the stock's valuation. CCOI's shares have seen a significant decline, prompting Madison to reconsider its position.
By Natalie PaceMar 16, 2026
Encompass Health Corporation's Q4 Performance: A Deeper Look into Madison Small Cap Fund's Perspective
Madison Small Cap Fund's Q4 2025 investor letter revealed challenges, with the fund underperforming its benchmark, the Russell 2000 Index. Healthcare was the weakest sector, notably impacting Encompass Health Corporation (EHC), a leading inpatient rehabilitation services provider. Despite strong fundamentals, EHC's defensive nature clashed with a market seeking offense. The fund remains cautiously optimistic about the speculative market losing momentum. This article delves into these findings and broader market implications.
By Natalie PaceMar 16, 2026
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial
Eli Lilly and Co. announced positive results from its Phase 3 ADorable-1 trial for Ebglyss (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis, showing significant skin improvement and itch relief, with a safety profile consistent with previous studies. The company plans to submit these data to regulators for a potential label update.
By Natalie PaceMar 16, 2026
Teradyne's Strong Market Performance Outshines Dow Jones
Teradyne, a prominent semiconductor company, has demonstrated exceptional market performance, significantly outpacing the Dow Jones Industrial Average. Despite a recent dip from its 52-week high, the company's stock has surged over the past three months and half-year, trading consistently above its key moving averages. This growth is attributed to its strategic focus on portfolio optimization and market expansion, reinforcing its leadership in the semiconductor equipment industry.
By Natalie PaceMar 16, 2026